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Pulmonary inflammation is a hallmark of many respiratory diseases such as asthma, chronic obstructive pulmonary disease
(COPD), and acute respiratory syndrome distress (ARDS). Most of these diseases are treated with anti-inflammatory therapy in
order to prevent or to reduce the pulmonary inflammation. Herbal medicine-derived natural products have been used in folk
medicine and scientific studies to evaluate the value of these compounds have grown in recent years. Many substances derived
from plants have the biological effects in vitro and in vivo, such as flavonoids, alkaloids, and terpenoids. Among the biological
activities of natural products derived from plants can be pointed out the anti-inflammatory, antiviral, antiplatelet, antitumor anti-
allergic activities, and antioxidant. Although many reports have evaluated the effects of these compounds in experimental models,
studies evaluating clinical trials are scarce in the literature. This review aims to emphasize the effects of these different natural
products in pulmonary diseases in experimental models and in humans and pointing out some possible mechanisms of action.
1. Introduction
Pulmonary diseases rate has been increasing and it is related
to causes of death for decades. Among the pulmonary
diseases, chronic obstructive pulmonary diseases (COPD),
asthma, and acute respiratory distress syndrome (ARDS) are
the most common and are linked to high mortality and/or
high morbidity rates [1–3].These pulmonary diseases have in
common the pulmonary inflammation which could be acute
or chronic and the orchestration of a lot of inflammatory
mediators [4].
Inflammation is a cellular response that can occur in the
lung induced by external or internal agents. Although it is
an important response in the organism, the chronic inflam-
mation could damage the lung. Lung inflammation involves
the activation of inflammatory cells, such as macrophages,
lymphocytes, neutrophils, and eosinophils, which is a source
of different kinds of inflammatory mediators such as his-
tamine, tumor necrosis factor (TNF-𝛼), interleukins, IL-1𝛽,
IL-4, IL-5, and IL-6, prostaglandins, leukotrienes, and nitric
oxide. The release of these inflammatory mediators is related
to the signals and symptoms observed in pulmonary diseases
such as loss of lung function, airway hyperresponsiveness and
obstruction, airway edema, mucus hypersecretion, and lung
remodeling [3, 4].
The treatment of the respiratory disorders often involves
the use of anti-inflammatory therapies and it is required
not only to counteract lung inflammation but also to avoid
the remodeling process and the destruction of lung tissue
preventing a decrement in lung function that is observed in
many patients [5]. Additionally, pulmonary diseases such as
emphysema and ARDS do not have proper treatments yet,
requiring more studies in alternative therapy [6, 7].
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Herbs have been used in folk medicine since many years
and the use of herbal-derived natural products as a thera-
peutic tool has been increasing considerably [8–10]. However,
several herbal-derived natural compounds significantly affect
cellular mechanisms and evidence of the benefic effects of
herbal-derived natural products in inflammatory pulmonary
diseases has been increasing [8].The use of these compounds
must be based on scientific evidence. The structures of the
various products cited in this review are presented in Figure 1.
Herein, we review the anti-inflammatory activity of herbal-
derived natural products with respect to three pulmonary
diseases, namely, asthma, emphysema, and ARDS (Table 1).
2. Evidence of Herbal-Derived Natural
Products in ARDS
ARDS is characterized by acute pulmonary inflammation
primary characterized by neutrophil infiltration, interstitial
edema, and hypoxemia, is often accompanied by aggressive
fibrosis, and is still one of the leading causes of death within
an intensive care unit [11–13].
The acute phase of ARDS is characterized by local inflam-
mation and systemic response [14]. Experimental and clinical
studies have sought to elucidate the complex mechanisms
involved in the pathogenesis of secondary injury. Several
mechanisms remain little understood; however, knowing the
functions of cytokines and inflammatory mediators involved
in the process helps us to clarify the process of injury and
repair in ARDS.
Some specific cells are able to secrete some soluble
protein called cytokines, which have the ability to modify the
behavior of other cells [15]. TNF-𝛼 and interleukin 1 beta and
8 (IL-1 𝛽 and IL-8) [15], cytokines classified as proinflam-
matory [14], are included among the cytokines involved in
acute phase of ARDS.
Patients with ARDS more than 72 hours usually evolve
into the late phase of ARDS which is characterized by having
diffuse alveolar damage that is sometimes irreversible [16].
Although mortality has been reduced due to the improved
control of ventilation, no effective pharmacological treatment
for the disease is available until now.
Many experimental studies seek evidence in natural
substances to help in treating this disease; however, no
evidence of the use of herbal medicine in patients with ARDS
was found. Several studies demonstrated that plants can
have effects on cell migration, anti-inflammatory, cytokines,
metalloproteinase, oxidative stress, and the downregulation
of several transcription factors making as a potential ther-
apeutic use in ARDS. Currently, the phytochemical groups
surveyed more with anti-inflammatory and antimicrobial
actions are the flavonoids, alkaloids, and glycosides [17–19].
Eriodictyol (1), a flavonoid isolated from the Chinese
herb Dracocephalum rupestre, has long been established as
an antioxidant and anti-inflammatory agent. Zhu et al. [20]
investigated the effects of eriodictyol on lipopolysaccharide-
(LPS-) induced acute lung injury (ALI) in mice and have
demonstrated that eriodictyol alleviates the LPS-induced
lung injury in mice by regulating the transcription factor
nuclear factor erythroid-2-related factor 2 (Nrf2) pathway
and inhibiting the expression of inflammatory cytokines in
macrophages.
Kuo et al. [21] showed that pretreatment with flavonoids
luteolin (2) reduced pulmonary hemorrhage and neu-
trophilic inflammation, as well as interstitial edema. The
control of pulmonary inflammation was due to the reduction
of cytokines such as TNF-𝛼, KC, and ICAM-1 content in the
bronchoalveolar lavage fluid (BALF).The control of oxidative
damage and lipid peroxidation was attributed to reduced
activity of catalase and superoxide dismutase activity. The
mechanism involved is related to the effects of luteolin in the
inhibition of NF-𝜅B and the MAPK activity.
Quercetin (3) is also evaluated in a LPS-induced exper-
imental ALI and it reduced the release of proinflammatory
cytokines in the BALF, such as TNF-𝛼, IL1-𝛽, and IL-
6, by a heme oxygenase-1(HO-1) dependent pathway [22].
Other authors also demonstrated that quercetin is effective
in reducing serum cytokines TNF-𝛼, IL1-𝛽, IL-6, and nitric
oxide (NO) and the mechanism involves an increase in IL-
10 secretion, an anti-inflammatory cytokine [23]. In addition
to these cytoprotective effects, quercetin also decreased the
ratio of lung weight to body weight and MMP-9 activity [22,
23]. Quercetin also reduced lung permeability, the number
of macrophages and neutrophils, and the myeloperoxidase
activity.Wang et al. [23] also showed that quercetin is effective
in reducing COX-2, iNOS expression, HMGB1, and p65-
nuclear factor kappa B (NF-𝜅B) [23].
Kaempferol (4), naturally occurring flavonoid, when
evaluated in ALI models induced by LPS appeared effective
in reducing pulmonary edema as well as the bleeding and
thickness of the alveolar wall. The kaempferol also reduced
the inflammatory cells and total protein in the BALF and
cytokines including TNF-𝛼, IL-1𝛽, and IL-6. Despite the
increase in superoxide dismutase activity, the mechanism of
action is through the control of signaling pathways MAPK
and NF-𝜅B [24].
The dried root Paeonia lactiflora has been used as a
medicinal herb in traditional Chinese medicine for cen-
turies. The glucosides of peony (TGP), the water/ethanol
extract of the dried Paeonia lactiflora, contain more than
15 components, including paeoniflorin (5), albiflorin (6),
oxypaeoniflorin (7), benzoylpaeoniflorin (8), oxybenzoyl-
paeoniflorin (9), paeoniflorigenone (10), lactiflorin (11), gal-
loylpaeoniflorin (12), paeonin (13), paeonolide (14), and
paeonol (15). Using a model of LPS-induced ALI, He and
Dai [25] demonstrated that TGP markedly suppressed LPS-
induced NO production and inducible nitric oxide synthase
(iNOS) expression peritoneal macrophages from rats. In
addition, the production of reactive oxygen species from
LPS-stimulatedmacrophages was inhibited. Kim andHa [26]
showed that paeoniflorin (5), the principle component of
TGP, was effective in inhibiting theNO and PGE2 production
induced by LPS in stimulated macrophages. Further exper-
iments showed that paeoniflorin inhibited LPS-stimulated
TNF-𝛼 and interleukin- (IL-) 1𝛽 release and promoted an
increase in IL-10 production [27].
Mitraphylline (16) is the major pentacyclic oxindolic
alkaloid presented inUncaria tomentosa and has traditionally
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Figure 1: Natural products (1–45) from plants with effects in inflammatory lung diseases.
been used to treat inflammatory diseases [28]. However, the
specific role ofmitraphylline in inflammation is still not clear.
Some studies provided its ability to inhibit proinflammatory
cytokines, such as TNF-𝛼, through NF-𝜅B-dependent mech-
anism. TNF-𝛼 primes neutrophils and modulates phagocytic
and oxidative burst activities in inflammatory processes [29].
Recently, Montserrat-de la Paz et al. [30] investigated the
effects on mitraphylline in LPS-activated human primary
neutrophils including activation of surface markers by FACS
and the expression of inflammatory cytokines. The treat-
ment with mitraphylline reduced the activated neutrophils
CD16(+)CD62L(−) and the expression and secretion of
proinflammatory cytokines (TNF-𝛼, IL-6, or IL-8) to the
levels obtained in basal control condition.
Asperuloside (17), an iridoid glycoside found in Herba
Paederiae, is a product from traditional Chinese herbal
medicine. Qiu et al. [31] investigated the protective effects
of asperuloside on inflammatory responses in a LPS-induced
ALI model. This compound was able to downregulate TNF-
𝛼, IL-1𝛽, and IL-6 levels both in vitro and in vivo. Addition-
ally, the treatment with asperuloside also reduced the lung
wet-to-dry weight, histological alterations, and myeloperoxi-
dase activity in this model. The mechanism involved in the
effects of asperuloside is related to the phosphorylation of
the inhibitor of NF-𝜅B (I𝜅B𝛼), extracellular signal-related
kinases 1 and 2 (ERK1/2), and c-Jun N-terminal kinase (JNK)
and p38 mitogen-activated protein kinase (p38MAPK) in
LPS-induced lung inflammation. These results indicate that
asperuloside exerts its anti-inflammatory effect in correlation
with the inhibition of proinflammatory mediators through
suppressing NF-𝜅B translocation and MAPK phosphoryla-
tion.
The rhizome of Picrorhiza scrophulariiflora has been
described as part of Asian traditional medicine for the
treatment of rather a broad range of diseases [32], including
tumors and liver infections. Picroside II (18) is known as
a major constituent of this plant [33] and it was reported
that the herb has immunomodulatory and anti-inflamma-
tory functions. The ethanol extract of P. scrophulariiflora
suppresses redox-sensitive inflammation [34], while crude
extract of P. scrophulariiflora reduces the classical pathway of
complement activation, the production of ROS by activated
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Table 1: Herbal-derived natural compounds effects in lung inflammation and diseases.
Inflammatory mediators Effects in Reference
Natural products
Eriodictyol (1)
Regulation of Nrf2 pathway and inhibiting the expression of
inflammatory cytokines TNF-𝛼, IL-6, IL-1𝛽, and in BALF and
serum
ALI model [20]
Luteolin (2) Reduction of TNF-𝛼, KC, ICAM-1, SOD, activations of MAPK,and NF-𝜅B pathways and neutrophils inflammation ALI model [21]
Quercetin (3)
Reduction of TNF-𝛼, IL1-𝛽, IL-5, and IL-6 in BALF, NO COX-2,
iNOS expression, HMGB1, and p65NF-𝜅B. Increase IL-10
secretion.
ALI model,
asthma model [22, 23, 67]
Kaempferol (4) Reduction of inflammatory cells, activation of MAPK, and NF-𝜅Bpathways ALI model [24]
Mitraphylline (16) Reduction of IL-1𝛼, IL-1𝛽, IL-17, TNF-𝛼, IL-6, and IL-8. ALI model [29, 30]
Asperuloside (17) Reduction of TNF-𝛼, IL-1𝛽, and IL-6 levels ALI model [31]
Eugenol (19) Inhibition of superoxide radicals from xanthine oxidase systemand the generation of hydroxyl radical ALI model [39]
Sakuranetin (30)
Reduction of eosinophils, TNF-𝛼, IL-5, IL-1𝛽, M-CSF, and
RANTES and inhibition of NF-𝜅B in lung, MMP-9-positive, and
MMP-12-positive cells and increased TIMP-1 expression.
Asthma model,
elastase model [62, 88]
Kuwanon G (31) Reduction of IL-4, IL-5, and IL-13 in the sera and BALF Asthma model [63]
Naringin (37) Reduction of IL-4, IL-5, IL-13, and INF-𝛿 levels Asthma model [70, 71]
Apigenin (38) Reduction of eosinophil infiltration in lung tissue and IL-6,TNF-𝛼, and IL-17A levels Asthma model [72]
Extracts of plants
Astragalus membranaceus Reduction of eosinophils and lymphocyte infiltration. ModulateTh1/2 immune balance and activates PPAR Asthma model [69]
Boerhavia procumbens Reduction in the infiltration of eosinophils and lymphocytes inlungs Asthma model [65]
Ocimum gratissimum Reduction in the infiltration of eosinophils and IL-4 expression Asthma model [66]
Punica granatum Reduction of eosinophils and cytokines IL-1𝛽 and IL-5 Asthma model [75]
Siegesbeckia glabrescens Reduction of the expression of iNOS and COX-2, cytokine IL-4,IL-5, and IL-13 Asthma model [78]
Herbal formula PM014 Reduction of neutrophils, macrophages, and lymphocytes in BALF,TNF-𝛼, and IL-6 levels, Elastase model [89]
Callicarpa japonica Reduction of neutrophil infiltration, cytokines IL-6 and TNF-𝛼,and the oxidative stress
Cigarette smoke
model [90]
neutrophils, and the proliferation of T lymphocytes [35]. Noh
et al. [36] using a model of RAW 264.7 cells and also an in
vivomodel of LPS-induced ALI showed that Picroside II was
effective in suppressing neutrophilic lung inflammation and
that the possible anti-inflammatory effect of Picroside II was,
at least in part, associated with TGF-𝛽 signaling.
The phenylpropanoid eugenol (19) is a substance present
in essential oils of various plants, and it is part of a phenolic
group with a recognized antioxidant capacity [37]. Eugenol
can prevent lipid peroxidation [38] and also inhibit the
formation of superoxide radicals from xanthine oxidase
system and the generation of hydroxyl radical [39, 40]. The
relationship between oxidative stress and inflammation in
ARDS is not completely understood; however, it is fact that
the reduction of oxidative stress culminates with reduction
in inflammatory mediators release by inflammatory cells
[41]. Murakami et al. [42] showed that eugenol inhibits
the transcription of NF-𝜅B and COX-2 stimulated by LPS.
According with these findings, Huang et al. [43] showed
that animals which received eugenol have reduction in
proinflammatory cytokines and inflammatory cells in BALF
due to an antioxidative effect of this product and by inhibition
of the transcription of NF-𝜅B in lung homogenate.
As reported in the literature [44, 45], the crude extracts
from fruits and leaves of Morinda citrifolia have been used
in traditional medicine for the treatment of inflammation
and pulmonary diseases. These effects could be associated
with the presence of several antioxidant natural products
such as iridoid glycosides (deacetylasperulosidic acid, 20
and asperulosidic acid, 21), and flavonoids (quercetin-
3-O-𝛼-L-rhamnopyranosyl-(1→6)-𝛽-D-glucopyranoside,
22 and kaempferol-3-O-𝛼-L-rhamnopyranosyl-(1→6)-𝛽-
D-glucopyranoside, 23). Additionally, turmeric (Curcuma
longa) and ginger (Zingiber officinale) displayed an important
effect in inflammation, including lung and pulmonary, which
could be due the presence of curcumin (24) [46, 47].
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The presence of different polyphenol derivatives in green
tea (Camellia sinensis leaves) such as catechin (epicate-
chin, 25; epigallocatechin, 26; epicatechin gallate, 27; and
epigallocatechin gallate, 28) is associated with the potent
chemopreventive agent against lung cancer formation in
animal studies [48]. The reported mechanisms for activity of
green tea against cancer are antioxidation, induction of phase
II enzymes, inhibition of TNF-𝛼 expression and release,
inhibition of cell proliferation, and induction of apoptosis.
Finally, considering that antioxidant derivatives could be
associated with anti-inflammatory effects and, consequently,
with the lung diseases treatment, the red wine could be
considered an important source of bioactive compounds due
to accumulation of stilbenes, especially resveratrol (29). As
reported [49, 50], treatment using resveratrol inhibits lung
cancer cell growth via induction of premature senescence
through ROS-mediated DNA damage.
Many other natural compounds have been effective in the
reduction of proinflammatory cytokines both in BALF, in the
lung tissue, and in serum [51–53]. Despite evidence showing
that many natural substances were effective in controlling
the alterations observed in models of in ALI, there is no
evidence, at least in our knowledge, related to the effects
of herbal medicine in ARDS in humans. There is still need
for more studies to better understanding the mechanisms
involved and to elucidate the efficacy and the safety of
natural compounds to a subsequent clinical application in
patients.
3. Evidence of Herbal-Derived Natural
Products in Bronchial Asthma
Asthma is a heterogeneous and complex chronic respiratory
disease associated with several phenotypes. Generally, the
symptoms of asthma are recurrent episodes of wheezing,
breathlessness, chest tightness, and coughing particularly at
night or early in the morning that are typically associated
with variable airflow obstruction [1]. Approximately 10%
of the world population is affected by the disease, varying
from 1 to 18%. Clinically the patients present symptoms such
as wheeze, dyspnea, chest tightness, and cough that vary
over time and in intensity, which is associated with airflow
limitation [1].
Asthma depends on the interaction of genetic and envi-
ronmental factors featured by the activation of theTh2 profile
cells, eosinophils, mast cells, and neutrophils [54]. Several
mediators/modulators are involved in asthma pathogenesis
and in hyperresponsiveness such as Th2 cytokines (IL-5, IL-
4, and IL-13), IL-17, leukotrienes, nitric oxide, Rho kinase,
cholinergic system, and others that were clearly evaluated in
humans and animal models [1, 55–59].
The long-term goals for asthma treatment are to achieve
control of symptoms with low side effects of the medications
and reduce the risk of exacerbations and of fixed airflow
obstruction frequently associated with the remodeling pro-
cess. Corticosteroids are considered the gold-standard treat-
ment for asthma, including during an acute asthma attack.
The corticosteroids are responsible for inhibiting numerous
anti-inflammatory pathways. Inhaled or oral corticosteroids
are widely used, acting as a powerful anti-inflammatory drug.
Some patients (10 to 25%) remain symptomatic despite
optimal glucocorticosteroid therapy and there is evidence of
persistent airway and distal lung inflammation and suffering
from the unwanted effects of high-prolonged corticoid ther-
apy, such as osteoporosis, cataracts, and diabetes. In addition,
corticosteroids do not act directly on pulmonary structural
changes better regulating the different processes involved
in the pathophysiology of asthma [1, 60, 61]. However, the
discovery of new drugs for the control of the disease is
essential in patients with severe corticosteroid-insensitive
asthma and also for the decrease of the collateral systemic
effects of steroid use.
Several studies demonstrated anti-inflammatory effects
of flavonoids of different plants in experimental asthma treat-
ment. Toledo et al. [62] investigated the effects of sakuranetin
(30), a flavonoid from Baccharis retusa, in an asthma model
and found that this flavonoid induces a reduction of the Th2
cytokines such as IL-5, RANTES, and Eotaxin in sensitized
mice. Sakuranetin also reduced the number of inflammatory
cells in the lung, particularly eosinophils, and IgE title in
the animals sensitized with ovalbumin and treated with this
flavonoid. The effects of sakuranetin seem to be related to
the inhibition of NF-𝜅B in lung. Reinforcing the effects of
flavonoids in asthma, Jung et al. [63] demonstrated that
kuwanon G (31), a flavonoid isolated from root bark of
Morus alba L., decreases the levels of IgE in ovalbumin-
induced allergic asthma in mice. Further, considering the
inflammatory mediators involved in asthma, kuwanon G
significantly decreased the levels of IL-4, IL-5, and IL-13
in the sera and in bronchoalveolar lavage of asthma mice.
Chung et al. [64] demonstrated using flavonoids kaempferol-
3-O-rhamnoside (32) and kaempferol (4) a reduction in
inflammatory cell numbers in BALF and also an inhibition
in the increase in Th2 cytokines (IL-4, IL-5, and IL-13) and
TNF-𝛼 protein levels.
The effects of herbal-derived natural compounds on
eosinophilic infiltration in differentmurinemodels of asthma
have been previously demonstrated. Using amethanol extract
from Boerhavia procumbens, Bokhari and Khan [65] demon-
strated a reduction in the infiltration of eosinophils and
lymphocytes in lungs of toluene diisocyanate (33) exposure
in rats. Costa et al. [66] found that Ocimum gratissimum, a
plant rich in rosmarinic acid (34) and commonly used in folk
medicine in Brazil, attenuates the eosinophilic airway inflam-
mation and reduced mucus production and IL-4 expression
in an experimental model of respiratory allergy to Blomia
tropicalis. The administration of flavonoid quercetin (3) in
ovalbumin immunized mice, suggested a reduction in the
number of eosinophil in the BALF, neutrophil in peripheral
blood, and the levels of IL-5 in lung homogenate [67].
The administration of wogonin (35), a flavone derived
from a plant called Scutellariae radix, reduced the total IgE
and ovalbumin specific IgE levels compared with the oval-
bumin challenged group [68]. Astragalus membranaceus, a
traditional Chinese herb, decreases airway allergic responses,
including specific IgE, eosinophilia, lymphocyte infiltration,
and airway inflammation, modulatesTh1/2 immune balance,
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and activates PPAR in amurine asthmamodel [69].This plant
is composed essentially by saponins (huangqiyiesaponin C,
36) and flavonoids (quercetin, 3 and kaempferol, 4), which
are known anti-inflammatory metabolites.
Naringin (37), a component isolated from the dried
unripe or ripe fruit peel of Citrus grandis “tomentosa”
(Exocarpium Citri Grandis), reduced enhanced cough and
airway hyperresponsiveness and inhibited the increases in
the leukocytes, IL-4, IL-5, and IL-13, in BALF in a model of
asthma using guinea pigs [70]. Further, using the same com-
ponent, Guihua et al. [71] also demonstrated an inhibition
of ovalbumin-induced increased airway resistance (Raw) and
eosinophil infiltration, as well as IL-4 and INF-𝛿 levels after
naringin administration.The apigen (38), a related flavonoid,
also inhibited OVA-induced increases in Raw and eosinophil
infiltration in lung tissue associated with a reduction in IL-6,
TNF-𝛼, and IL-17A levels [72].
Curcumin (24), a natural product isolated from the
plant Curcuma longa, improved the airway inflammation
and reversed the increased levels of Notch signaling pathway
(Notch1/2) receptors and the transcription factor GATA3
in ovalbumin-sensitized mice [73]. Other studies with
intranasal curcumin administration demonstrated a protec-
tive effect on the recruitment of inflammatory cells to the
airways and in the remodeling features such as peribronchial
and airway smoothmuscle thickening andmucus secretion in
ovalbumin-induced chronic asthma in a murine model [74].
de Oliveira et al. [75] demonstrated the anti-inflamma-
tory effects of Punica granatum which inhibited leukocytes
recruitment in BALF, especially eosinophils, and decreased
cytokines (IL-1𝛽 and IL-5) release in the lungs of OVA-
sensitized BALB/c mice. This effect could be associated
with the presence of different metabolites such as alkaloids,
terpenoids, and flavonoids.
The remodeling process in asthmatics induces significant
structural changes in proximal and distal airways as well
as in the distal lung. This process is associated with airway
smooth muscle hypertrophy and hyperplasia, mucous gland
hyperplasia, and increased thickness of the airway wall [54,
76, 77]. It is well known that inflammatory mediators such
as IL-4 and IL-13 as well as the persistence of chronic
inflammation in airways are involved in the remodeling
process, so natural compounds that inhibit the inflamma-
tory process in asthma may also prevent the remodeling
process.
Extracts of Siegesbeckia glabrescens, a traditional medici-
nal plant in Korea, reducedmucus overproduction in airways
in a asthmamurine model, decreased the expression of iNOS
and COX-2, reducing the number of inflammatory cells in
BALF and the cytokine release (IL-4, IL-5 and IL-13) [78].
Using an inhalator approach, the treatment with Lavender
essential oil (Lvn) in a murine model of bronchial asthma
reduced the airway resistance (Raw) and the number of
eosinophils recovered in BALF and also in peribronchial and
perivascular tissues. Furthermore, Lvn reduced mucous cell
hyperplasia and the mRNA expression of Muc5b without
significantly changing the mRNA expression of Muc5ac [79].
Chemically, this plant showed to be composed by quercetin
flavonoid derivatives such as 3,4󸀠-O-dimethylquercetin (39),
3,7-O-dimethylquercetin (40), 3-O-methylquercetin (41),
and 3,7,4󸀠-O-trimethylquercetin (42) [80].
Wang et al. [81] contribute to the mechanisms involved
in the anti-inflammatory effects of Yupingfeng Pulvis in
an asthma model, which is related to a reduction of the
proportion ofTh17 cells, whereas the population of Treg cells
in BALF was increased, inhibiting the pulmonary proinflam-
matory cytokines release in treated animals.
Several studies have associated the diet with the develop-
ment of allergic diseases. In this context, low consumption
of fruits and vegetables rich in antioxidant substances is
associated with high risk of asthma and atopic diseases
development. However, the diet rich in antioxidants and
lipids particularly during pregnancy and childhood is related
to reducing the allergic diseases prevalence [82]. In a
population-based study, the asthma incidence was lower at
higher quercetin (3) and naringin (37) flavonoids intake from
the diet [83]. However, Smith et al. [35] showed that the
consumption of soy isoflavone such as genistin (43) and
genistein (44) did not improves asthma control in adolescents
and adults patients with poorly controlled asthma.
Studying asthmatic patients, Watson et al. [84] investi-
gated the effects of the purple passion fruit peel (PFP) extract
and observed that patients who received oral administration
of purple passion fruit peel showed a reduction of wheeze
and cough as well as shortness of breath. An herbal known
as Umckaloabo with contains root extract of Pelargonium
sidoides seems to be effective in the treatment of acute res-
piratory infections [85, 86]. Additionally, Tahan and Yaman
[87] demonstrated that Umckaloabo reduced asthma attack
during upper respiratory tract viral infections in asthmatic
children which demonstrated a minor cough frequency and
nasal congestion. Collectively, these data suggest that high
intake of fruit and vegetables had a negative association with
risk of asthma.
4. Evidence of Herbal-Derived Natural
Products in COPD
Chronic obstructive pulmonary disease (COPD) is the major
cause of chronic respiratory morbidity and mortality and
the fifth cause of death worldwide [91, 92] and it is char-
acterized by a persistent airflow limitation associated with
an enhanced chronic inflammatory response to noxious
particles or gases [92]. This inflammatory response usually
promotes parenchymal destruction (resulting in emphysema)
and small airways fibrosis [92]. The incidence and severity of
chronic obstructive pulmonary disease (COPD) are growing
affecting between 100 and 150 million people worldwide [92].
COPD is characterized by persistent airflow limitation
that is usually progressive and is associated with an enhanced
chronic inflammatory response to noxious particles or gases
in the airways and the lung [92]. The inhalation of cigarette
smoke and other environmental pollutants stimulates the
alveolar macrophages in the lung epithelial cells to generate
reactive oxygen species and reactive nitrogen species [93] in
excess causing an imbalance in the system.
The protease/antiprotease imbalance is still recognized as
the main mechanism enrolled in emphysema development
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[94–97]. The majority of studies in animal models have
attested the importance ofMMPs in parenchymal destruction
in emphysema [98–100], especially the MMP-12; other pro-
teases such as neutrophil elastase from the serine proteases
family are described in humans emphysema [101].
These proteases are produced by neutrophils, macropha-
ges, and bronchial epithelial cells [102–104]. In emphysema,
there is an increase in neutrophils in sputum and airways,
while macrophages are predominate in parenchyma and in
bronchoalveolar lavage, suggesting an importance of these
cells in distal airways [105, 106]. In this context, elastase
secreted by neutrophils andmacrophagesmay play an impor-
tant role in lung tissue destruction [107, 108].
The proteolytic attack of extracellular matrix components
of lung parenchyma by proteases induces alveolar walls
destruction associated with a dynamic tissue repair and
remodeling process, involving a reorganization of extracellu-
lar matrix (ECM) components [109]. However, biochemical
and histological studies have demonstrated that the remodel-
ing of col I and III, elastin, and fibrillin results in loss of lung
elasticity [110–112].
The COPDmanagement is divided into some approaches
such as the reduction of risk factors and therapeutic man-
agement of stable disease and of the exacerbations. However,
no currently available treatments reduce the progression or
even adequately suppress the inflammation in small airways
and lung parenchyma [92]. Therefore, we have to consider
the importance of new approaches in emphysema studies,
especially in concern with the new targets to avoid the
progression of the alveolar walls destruction and remodeling.
There are a large number of protein families that are able
to inhibit serine, cysteine, andmetalloproteases [113], and the
mechanisms of inhibition could be attributed to the catalytic
mechanisms of proteases action or a mechanism-unrelated
blockage of the specific active sites [113].
Animal models of emphysema have been used as features
to better clarify the pathogenesis of such disease and the
most used are the elastases and cigarette-induced models.
However, both of them showed advantages and disadvantages
that have been considered for each experimental approach.
Although, the CS-induced model is suggested as the best
to reproduce the pathogenesis of humans emphysema; the
parenchymal destruction is mild even after long time of
exposure, whereas the elastase instillations produce severe
emphysema, depending on the dose, in short times [114–116],
but, so far it is not a model that resembles the physiology of
this disease as in humans.
Several antioxidant agents such as thiol molecules,
polyphenols derived from natural products, and other sub-
stances such as curcumin, resveratrol, andquercetin have
been evaluated in models of emphysema. Considering that
the physiopathology of COPD involves oxidative stress and
protease-antiprotease unbalance, substances that affect these
aspects should be considered to be beneficial in COPD.
There are studies showing the effects of protease inhibitors
against the emphysema development and progression in
experimental models [94, 117, 118].
In a previous study, Lourenc¸o et al. [119] demonstrated
in elastase-induced model that a treatment with a serine
protease inhibitor from the cattle tick (rBmTI-A) atten-
uated emphysema in treated mice before and after the
elastase intranasal instillation. The rBmTI-A treatment was
responsible to reverse the loss of elastic recoil, the alveolar
enlargement, and the total inflammatory cells amount in
bronchoalveolar lavage. Indeed, it was sufficient to reduce
the density of positive cells formetalloprotease-12, suggesting
that this MMP could be a therapeutic target [119].
Wright et al. [120] showed in guinea pigs acutely or
chronically exposed to cigarette smoke that the treatment
with a serine elastase inhibitor (ZD0892) decreased the
inflammatory activity mediated in part by neutrophils with
a reduction in parenchymal destruction [120]. Also, Kuraki
et al. [121] performed a prior treatment with an oral inhibitor
for neutrophil elastase (ONO-6818) before the induction of
acute lung injury and emphysema in rats by intratracheal
administration of human neutrophil elastase. They observed
that theONO-6818 treatment inhibited lung hemorrhage and
the neutrophils increase at the acute phase and that, in long
term, it prevented HNE-induced emphysema.
Takayama et al. [118] performed a posttreatment with a
neutrophil elastase inhibitor (NEI; ONO-5046) after intesti-
nal ischemia-reperfusion in rats and observed a reduction
in neutrophil activation in pulmonary vessels and neutrophil
infiltration in the lungs, preventing the lung injury develop-
ment.
Considering the herbal medicine, few studies have eval-
uated the effects of these compounds in emphysema. More-
over, it is difficult to isolate the effects of these compounds
in the inhibition of elastase activity or in the inflammatory
mediators. In this context, Sartor et al. [122] showed that
the flavonoid epigallocatechin gallate (28) is an inhibitor
of leukocyte elastase. Lee et al. [89] showed that an herbal
formula PM014 reduced inflammatory cells in BALF and the
levels of TNF-𝛼 and IL-6 in a model of elastase+LPS-induced
emphysema.
More recently, Lee et al. [90] evaluated the effects of
Callicarpa japonica, a traditionally herbal used in orien-
tal countries to treat inflammatory diseases. The obtained
results indicated that Callicarpa japonica extracts reduced
neutrophil infiltration, the production of cytokines IL-6 and
TNF-𝛼, and the oxidative stress in amodel of cigarette smoke.
Additionally, the authors found a reduction in the production
of mucus in lung tissue of cigarette smoke animals. The
mechanisms involvedwere evaluated in vitro andwere related
to a reduction in the phosphorylation of ERK.
Other traditional Chinese medicines have been used
to treat chronic obstructive pulmonary disease (COPD) in
patients [123, 124]. In this context, Li et al. [123] demonstrated
that the Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules, and
Yi-Qi Zi-Shen granules, three common Chinese medicines,
have beneficial effects onmeasured outcomes in stable COPD
patients over the 6-month treatment. Moreover, Li et al. [124]
demonstrated the benefic effects of the three Tiao-Bu Fei-
Shen (Bu-Fei Jian-Pi, Bu-Fei Yi-Shen, and Yi-Qi Zi-Shen
granules) in the reduction in the levels of IL-1𝛽, TNF-𝛼, p-
NF-𝜅B, p-I𝜅B𝛼, TGF-𝛽1, and Smad2 in COPD rats.
Song et al. [125] studied the Picroside C (45), isolated
from Pseudolysimachion rotundum, and found that this
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Figure 2: Possible mechanism involved in the effects of herbal-derived natural products on pulmonary inflammation in respiratory diseases.
It is believed that the natural products derived from plants inhibit the pulmonary inflammation by the inhibition of the transcription of
NF-𝜅B to the nucleus, thus preventing the development of all the inflammatory processes triggered by allergen, cigarette smoke, virus, or
bacteria. Therefore, these products can reduce the inflammatory cytokines release and oxidative stress. These effects together culminate with
the improvement of lung function and with the reduction of pulmonary inflammation.
compound protects the neutrophil influx, the production of
reactive oxygen species, and the classical cytokines IL-6 and
TNF-𝛼 as well as the elastase activity. The author suggested
that the mechanism involved is the inhibition of the NF-𝜅B
pathway which counteracts the lung inflammation.
Our group also evaluated the effects of sakuranetin in
model of elastase-induced emphysema. We found that saku-
ranetin (30), isolated from Baccharis retusa, prevented the
alveolar destruction in a model of elastase-induced emphy-
sema. Moreover, the authors showed that this compound
reduced lung remodeling and the levels of TNF-𝛼, IL-1𝛽, and
M-CSF in the BALF.Themechanisms involved are associated
with the inhibition of NF-𝜅B and oxidative stress in lung
[88].
At least, in our knowledge, only the group of Mukaida
et al. [126] has evaluated the effects of a natural compound
in COPD patients. The authors tested the effects of a mix
of six herbal compounds and found that elderly COPD
patients have reduced the intensity of the cough; however,
other parameters were not evaluated.These findings reinforce
the importance of oxidative stress and protease/antiprotease
imbalance in emphysema development and suggest oxidative
stress, MMP-12, and neutrophil elastase as a future targets for
emphysema therapy.
5. Conclusions
In conclusion, herbal medicine-derived natural products
can be considered as an alternative therapeutic potential
for respiratory diseases since several compounds showed
anti-inflammatory effects inhibition different inflammatory
mediators involved in respiratory diseases such as asthma,
ARDS, and COPD.The possible mechanisms involved in the
effects of natural products in pulmonary inflammation and
respiratory diseases are summarized in the Figure 2. Most of
the studies are pointing out the effects of natural products
on the inhibition of NF-𝜅B andMAPK pathways, besides the
antioxidant effects associated with these products. However,
the clinical trials using these compounds are scarce in the
literature and the safety and efficacy should be confirmed for
further studies.
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